Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 988 across all filing types
Latest filing 2026-01-22 Share Issue/Capital Cha…
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Pending Release of Shares from Voluntary Escrow 2 pages 237.8KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited regarding the pending release of shares from voluntary escrow. It references compliance with ASX Listing Rule 3.10A and details the number of shares and escrow release date. The content is focused on share release information and does not contain financial statements, management discussion, or detailed financial data. It is not a report but an announcement about share capital changes related to escrow release. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding share issues, stock splits, or other capital changes such as escrow release.
2026-01-22 English
CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS
Regulatory Filings
2026-01-20 English
Chinese NMPA Accepts New Drug Application for Illuccix 3 pages 231.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited dated 20 January 2026. It announces that the Chinese National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for Illuccix, a prostate cancer imaging agent. The content focuses on regulatory progress, clinical trial results, and strategic business updates related to the drug's approval process in China. There are no financial statements, detailed financial performance data, or comprehensive management discussion of financial results. The document is a regulatory announcement about a drug approval filing, not a full annual or interim report, earnings release, or investor presentation. It is also not a report publication announcement since it contains substantive information rather than just a notice of report availability. Therefore, the document fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2026-01-19 English
Telix Achieves FY25 Guidance - US$804M, Q4 Growth 6 pages 385.3KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited providing a detailed update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4 2025). It includes unaudited revenue figures for Q4 and full-year 2025, business highlights, clinical trial updates, strategic collaborations, and corporate updates. The document is not a full annual or interim report as it lacks comprehensive financial statements and detailed financial analysis. It is not a simple earnings release since it provides more extensive operational and strategic information beyond key financial highlights. It is not a report publication announcement because it contains substantive content rather than just announcing the release of a report. The document is a quarterly business update with financial data and operational commentary, fitting the definition of an Interim / Quarterly Report (IR).
2026-01-19 English
Appendix 2A updated 20 pages 541.3KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It details the issuance and quotation of securities resulting from the exercise of options, including specifics such as the number of options exercised, dates, and the nature of the securities. This type of document is a regulatory announcement related to capital changes, specifically the issuance and quotation of new shares following option exercises. It is not a financial report, earnings release, or management discussion, but rather a formal notification of a capital change event. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail confirm it is the announcement itself, not just a brief notice or report publication announcement.
2026-01-13 English
CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS
Regulatory Filings
2026-01-12 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.